TW201706263A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
TW201706263A
TW201706263A TW105115842A TW105115842A TW201706263A TW 201706263 A TW201706263 A TW 201706263A TW 105115842 A TW105115842 A TW 105115842A TW 105115842 A TW105115842 A TW 105115842A TW 201706263 A TW201706263 A TW 201706263A
Authority
TW
Taiwan
Prior art keywords
alkyl
methyl
indol
compound
ethyl
Prior art date
Application number
TW105115842A
Other languages
English (en)
Chinese (zh)
Inventor
多明尼克 阿曼斯
史帝芬 強 艾金森
邁可 大衛 巴克
馬修 坎貝爾
哈瓦 戴爾羅
克萊門 道爾特
奈爾 史都 咖頓
強 麗都
潔西卡 芳妮 雷諾
羅伯特 強 旭波
安 露薏絲 渥克
克里斯多佛 羅南 偉勒威
大衛 馬修 威爾森
Original Assignee
葛蘭素史密斯克藍智慧財產發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 葛蘭素史密斯克藍智慧財產發展有限公司 filed Critical 葛蘭素史密斯克藍智慧財產發展有限公司
Publication of TW201706263A publication Critical patent/TW201706263A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
TW105115842A 2015-05-21 2016-05-20 化合物 TW201706263A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164906P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
TW201706263A true TW201706263A (zh) 2017-02-16

Family

ID=56235853

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105115842A TW201706263A (zh) 2015-05-21 2016-05-20 化合物

Country Status (15)

Country Link
US (2) US10407407B2 (https=)
EP (1) EP3298003B1 (https=)
JP (1) JP6703553B2 (https=)
KR (1) KR20180005250A (https=)
CN (1) CN107849015B (https=)
AR (1) AR106863A1 (https=)
AU (1) AU2016264958B2 (https=)
BR (1) BR112017024678A2 (https=)
CA (2) CA2986199C (https=)
EA (1) EA033680B1 (https=)
ES (1) ES2945314T3 (https=)
IL (2) IL255666A (https=)
MX (1) MX387321B (https=)
TW (1) TW201706263A (https=)
WO (1) WO2016185279A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
JP6926126B2 (ja) 2016-02-23 2021-08-25 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Pad4のヘテロアリール阻害剤
KR102398941B1 (ko) * 2016-07-27 2022-05-17 패들락 테라퓨틱스, 인코포레이티드 Pad4의 공유결합성 억제제
JP7118951B2 (ja) 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Pad4のヘテロアリール阻害剤
MX2020003242A (es) * 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) * 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3746430A4 (en) 2018-02-02 2021-11-03 Padforward LLC INHIBITORS OF PROTEIN ARGININE DEIMINASES
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
PE20201185A1 (es) 2018-03-22 2020-11-03 Hoffmann La Roche Inhibidores de la oxacina monoacilglicerol lipasa (magl)
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
EP3833671B1 (en) 2018-08-08 2022-08-24 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
WO2020033488A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
ES2986417T3 (es) 2018-08-13 2024-11-11 Hoffmann La Roche Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
MA53220A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
ES2955037T3 (es) 2018-11-22 2023-11-28 Hoffmann La Roche Nuevos compuestos heterocíclicos
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
CA3155724A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
EP4034538A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG New heterocyclic monoacylglycerol lipase (magl) inhibitors
WO2021058443A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Fluorescent probes for monoacylglycerol lipase (magl)
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
EP4100405A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4143189A1 (en) * 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
BR112023002553A2 (pt) * 2020-08-12 2023-04-18 Jubilant Epipad LLC Composto, composição, uso do composto e uso da composição
MX2023002224A (es) 2020-09-03 2023-03-15 Hoffmann La Roche Compuestos heterociclicos.
WO2022140428A2 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
CN118679162A (zh) * 2021-11-15 2024-09-20 锐格药业公司 Pad4抑制剂及其用途
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
AP791A (en) 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
WO2010115736A2 (en) * 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
EP2515655B1 (en) * 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
RS55684B1 (sr) * 2012-07-26 2017-07-31 Glaxo Group Ltd 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4

Also Published As

Publication number Publication date
MX2017014714A (es) 2018-01-25
EP3298003A1 (en) 2018-03-28
US20200095227A1 (en) 2020-03-26
CN107849015B (zh) 2021-03-19
US10407407B2 (en) 2019-09-10
JP6703553B2 (ja) 2020-06-03
JP2018520105A (ja) 2018-07-26
US20180297983A1 (en) 2018-10-18
EA033680B1 (ru) 2019-11-15
WO2016185279A1 (en) 2016-11-24
AU2016264958B2 (en) 2020-10-29
US10815218B2 (en) 2020-10-27
AU2016264958A1 (en) 2017-12-07
CA3199601A1 (en) 2016-11-24
MX387321B (es) 2025-03-11
CN107849015A (zh) 2018-03-27
CA2986199A1 (en) 2016-11-24
CA2986199C (en) 2023-07-18
BR112017024678A2 (pt) 2018-07-31
ES2945314T3 (es) 2023-06-30
EP3298003B1 (en) 2023-04-19
IL278916A (en) 2021-01-31
EA201792517A1 (ru) 2018-04-30
AR106863A1 (es) 2018-02-28
IL255666A (en) 2018-01-31
KR20180005250A (ko) 2018-01-15

Similar Documents

Publication Publication Date Title
CN107849015B (zh) 作为pad4抑制剂的苯并咪唑衍生物
CN113227068B (zh) Glp-1r激动剂及其用途
TWI730032B (zh) 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN110248939B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
CN109790161B (zh) 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
CN104470919B (zh) 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
CN109661396B (zh) 作为rock抑制剂的螺稠合环状脲
TWI667233B (zh) 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
AU2016366398A1 (en) Bicyclic inhibitors of PAD4
CN107108566B (zh) 取代的2-氮杂双环化合物以及它们作为食欲素受体调节剂的用途
TW201629067A (zh) 稠合五環咪唑衍生物
TW201607948A (zh) 5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物、組合物及其使用方法
TW201443023A (zh) 作爲rock抑制劑之酞□酮及異喹啉酮
CN115348961A (zh) 杂环pad4抑制剂
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
TW201609708A (zh) 新穎2,5-經取代之嘧啶
TW202333663A (zh) Rxfp1促效劑
CN114980975A (zh) 二氢环戊二烯并异喹啉磺酰胺衍生物
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途
CN107709323B (zh) 羟基嘌呤类化合物及其应用
KR20190123307A (ko) 브로모도메인 억제제로서의 피라졸 유도체
CN109415366B (zh) [1,2,3]三唑并[4,5-d]嘧啶衍生物